Eli Muchtar, Amber B Koehler, Michael J Johnson, Kari G Rabe, Wei Ding, Timothy G Call, Jose F Leis, Saad S Kenderian, Suzanne R Hayman, Yucai Wang, Paul J Hampel, Matthew A Holets, Heather C Darby, Susan L Slager, Neil E Kay, Congrong Miao, Jennifer Canniff, Jennifer A Whitaker, Myron J Levin, D Scott Schmid, Richard B Kennedy, Adriana Weinberg, Sameer A Parikh
Monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) are clonal B-cell disorders associated with an increased risk of infections and impaired vaccination responses. We investigated the immunogenicity of recombinant zoster vaccine (RZV) in these patients. Individuals with MBL/untreated CLL and Bruton tyrosine kinase inhibitor (BTKi)-treated CLL patients were given two doses of RZV separated by 2 months. Responses assessed at 3 and 12 months from the first dose of RZV by an anti-glycoprotein E ELISA antibody assay and by dual-color Interferon-γ and Interleukin-2FLUOROSPOT assays were compared to historic controls matched by age and sex...
January 1, 2022: American Journal of Hematology